Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1631323 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2KMT2ARAB9ALMNAKDM4E | |
| SCHEMBL1631736 | 0.77 | TRPM5 (0.39) | — | |
| SCHEMBL1633393 | 0.77 | SMN1; SMN2 (0.37) | SMN1; SMN2KMT2ANPC1RAB9ADRD4 | |
| SCHEMBL1631928 | 0.77 | PSEN1 (0.51) | SMN1; SMN2KMT2ADRD4GRM2KDM4E | |
| SCHEMBL4820950 | 0.71 | PSEN1 (0.39) | KMT2AKDM4EMAPT | |
| SCHEMBL1633002 | 0.71 | L3MBTL1 (0.39) | KMT2ALMNAMAPTCYP2D6TSHR | |
| SCHEMBL1630933 | 0.69 | CYP19A1 (0.40) | KMT2AMAPTCYP2D6 | |
| SCHEMBL595170 | 0.68 | PSEN1 (0.37) | — | |
| SCHEMBL1631502 | 0.68 | PSEN1 (0.40) | RAB9AKDM4E | |
| SCHEMBL1632263 | 0.68 | MDM2 (0.33) | RAB9AMAPTTP53TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7399775-B2 | β-amyloid protein production/secretion inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7399775-B2 | β-amyloid protein production/secretion inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7399775-B2 | β-amyloid protein production/secretion inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20060241302-A1 | Morpholine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| EP-1640366-A1 | HETEROCYCLIC METHYL SULFONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-20050234109-A1 | to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| EP-1466898-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241302-A1 | Morpholine derivatives | APP, BACE1, SMS | SMN1; SMN2 314/4885KMT2A 3864/4885NPC1 2541/4885 |
| US-20050234109-A1 | to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine | APP, PSEN1, PSEN2 | SMN1; SMN2 136/4885KMT2A 1527/4885NPC1 863/4885 |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | APP, IAPP, BACE1 | SMN1; SMN2 1965/4885KMT2A 4830/4885NPC1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.